Skip to content

Study · Randomized controlled trial · n = 128 · 2010

13 results

Exenatide versus glibenclamide in patients with diabetes.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF

Diabetes technology & therapeutics1 Mar 2010Cited by 97 (Europe PMC)

PMID20151774 (opens in a new tab)DOI10.1089/dia.2009.0141 (opens in a new tab)PepBankPUB-20151774
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, exenatide reduced body weight while glibenclamide increased it.

    In plain wordsIn people with diabetes, exenatide reduced weight compared with weight gain with glibenclamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 microg twice a day titrated to 10 microg twice a day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Body weight and BMI decreased with exenatide and increased with glibenclamide.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, exenatide reduced BMI while glibenclamide increased it.

    In plain wordsIn people with diabetes, exenatide reduced BMI compared with an increase with glibenclamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBMI
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 microg twice a day titrated to 10 microg twice a day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Body weight and BMI decreased with exenatide and increased with glibenclamide.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, exenatide and glibenclamide produced similar HbA1c improvements.

    In plain wordsIn people with diabetes, exenatide and glibenclamide improved HbA1c similarly.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHbA1c
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice a day titrated to 10 microg twice a day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    A similar improvement of HbA(1c), FPG, and PPG was obtained in both groups, whereas FPI decreased with exenatide and increased with glibenclamide.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, exenatide and glibenclamide produced similar fasting glucose improvements.

    In plain wordsIn people with diabetes, exenatide and glibenclamide improved fasting glucose similarly.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeFasting plasma glucose
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice a day titrated to 10 microg twice a day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    A similar improvement of HbA(1c), FPG, and PPG was obtained in both groups, whereas FPI decreased with exenatide and increased with glibenclamide.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, exenatide and glibenclamide produced similar postprandial glucose improvements.

    In plain wordsIn people with diabetes, exenatide and glibenclamide improved glucose after meals similarly.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePostprandial plasma glucose
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice a day titrated to 10 microg twice a day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    A similar improvement of HbA(1c), FPG, and PPG was obtained in both groups, whereas FPI decreased with exenatide and increased with glibenclamide.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, fasting insulin decreased with exenatide and increased with glibenclamide.

    In plain wordsIn people with diabetes, fasting insulin decreased with exenatide and increased with glibenclamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFasting plasma insulin
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice a day titrated to 10 microg twice a day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    A similar improvement of HbA(1c), FPG, and PPG was obtained in both groups, whereas FPI decreased with exenatide and increased with glibenclamide.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, HOMA-IR decreased with exenatide but not glibenclamide.

    In plain wordsIn people with diabetes, insulin resistance decreased with exenatide but not glibenclamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHOMA-IR
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice a day titrated to 10 microg twice a day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The HOMA-IR index decreased and the HOMA-beta index increased with exenatide but not with glibenclamide.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, HOMA-beta increased with exenatide but not glibenclamide.

    In plain wordsIn people with diabetes, the beta-cell function index increased with exenatide but not glibenclamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHOMA-beta
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice a day titrated to 10 microg twice a day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The HOMA-IR index decreased and the HOMA-beta index increased with exenatide but not with glibenclamide.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, exenatide did not decrease the proinsulin to insulin ratio, unlike glibenclamide.

    In plain wordsIn people with diabetes, exenatide did not reduce the proinsulin to insulin ratio, unlike glibenclamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeProinsulin to insulin ratio
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice a day titrated to 10 microg twice a day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    A decrease of PPr was reported in both groups, but only glibenclamide decreased the PPr/FPI ratio.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, resistin decreased with exenatide and increased with glibenclamide.

    In plain wordsIn people with diabetes, resistin decreased with exenatide and increased with glibenclamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseResistin
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Inflammation markers · Metabolic and weight
    Studied dose
    5 microg twice a day titrated to 10 microg twice a day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Resistin and RBP-4 decreased with exenatide and increased with glibenclamide.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, RBP-4 decreased with exenatide and increased with glibenclamide.

    In plain wordsIn people with diabetes, RBP-4 decreased with exenatide and increased with glibenclamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseRetinol binding protein-4
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Inflammation markers · Metabolic and weight
    Studied dose
    5 microg twice a day titrated to 10 microg twice a day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Resistin and RBP-4 decreased with exenatide and increased with glibenclamide.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, Hs-CRP decreased with exenatide but did not change with glibenclamide.

    In plain wordsIn people with diabetes, Hs-CRP decreased with exenatide but did not change with glibenclamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHigh-sensitivity C-reactive protein
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    5 microg twice a day titrated to 10 microg twice a day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    A decrease of Hs-CRP was obtained with exenatide, whereas no variations were observed with glibenclamide.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 13HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In patients with diabetes, plasma proinsulin decreased in both exenatide and glibenclamide groups.

    In plain wordsIn people with diabetes, proinsulin decreased with both exenatide and glibenclamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePlasma proinsulin
    Study

    n = 128

    Comparator
    glibenclamide
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    A decrease of PPr was reported in both groups, but only glibenclamide decreased the PPr/FPI ratio.
    1 context sentence
    Summary · context
    One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 microg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 microg twice a day or glibenclamide 5 mg three times a day.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.